NEOTORCH Trial: Perioperative Toripalimab + Chemo in Resectable NSCLC – Phase 3 Results.

4 Views

  • Thanks! Share it with your friends!

    You disliked this video. Thanks for the feedback!

admin
Published
Explore the results of the NEOTORCH randomized clinical trial, evaluating perioperative toripalimab plus chemotherapy in patients with resectable non–small cell lung cancer (NSCLC). This phase 3 study investigates both neoadjuvant and adjuvant use of toripalimab to improve clinical outcomes in early-stage NSCLC.

???? Stay ahead in thoracic oncology with the latest clinical trial data.

#NEOTORCH #NSCLC #Toripalimab #LungCancerTreatment #Immunotherapy #CancerResearch.
Category
Oncology
Be the first to comment

Up Next